NASDAQ:ESLA Estrella Immunopharma Earnings Date & Estimates $0.51 0.00 (-0.94%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$0.52 +0.01 (+0.97%) As of 11/13/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Estrella Immunopharma is estimated to report earnings on Wednesday, December 2, 2026. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement Announcement DateDecember 2, 2026 Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Estrella ImmunopharmaEstrella Immunopharma is expected to post earnings of -$0.08 per share. In the same quarter a year earlier Estrella Immunopharma reported -$0.13 per share. Estrella Immunopharma last reported on August 13, 2026, posting -$0.05 per share and beating the -$0.09 consensus estimate. Estrella Immunopharma has beaten the consensus EPS estimate in 4 of its last 4 quarters.Consensus EstimatesConsensus EPS-$0.08Prior-Year EPS-$0.13Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.05 (Beat by +$0.04)EPS Beat Rate4 of last 4 quartersPrepare for the Earnings CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Estrella Immunopharma Earnings FAQ When does Estrella Immunopharma report earnings? Estrella Immunopharma (NASDAQ:ESLA) is estimated to report earnings on Wednesday, December 2, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What is the consensus EPS estimate for Estrella Immunopharma? Analysts expect Estrella Immunopharma to post earnings of -$0.08 per share for the quarter. Estrella Immunopharma Earnings HeadlinesEstrella Immunopharma Names Cynthia Pussinen CEO, Succeeding Cheng LiuOctober 28, 2026 | rttnews.comEstrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board of DirectorsOctober 26, 2026 | finance.yahoo.comWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 14 at 1:00 AM | Base Camp Trading (Ad)Estrella Immunopharma (ESLA) stock soars 18%: what's driving the surgeOctober 22, 2026 | msn.comEstrella Immunopharma, Inc. Activates Intermountain Health LDS Hospital As Fifth Clinical Site For Phase I/II STARLIGHT-1 Trial In B-Cell Non-Hodgkin?s LymphomaOctober 16, 2026 | marketscreener.comMEstrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion PhaseOctober 15, 2026 | finance.yahoo.comSee More Estrella Immunopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Estrella Immunopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Estrella Immunopharma and other key companies, straight to your email. Email Address About Estrella ImmunopharmaEstrella Immunopharma (NASDAQ:ESLA) (NASDAQ: ESLA) is a clinical-stage biopharmaceutical company focused on developing cellular immunotherapies for cancer and other serious diseases. The company’s work centers on genetically engineered T-cell therapies designed to recognize and destroy target cells. Estrella’s lead program is EB103, a CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy being developed for the treatment of certain B-cell malignancies. The company has described EB103 as being based on its ARTEMIS platform, which is intended to support targeted immune-cell activity while addressing some limitations associated with conventional CAR-T therapies. Estrella became a publicly traded company through a business combination with TradeUP Global Corporation. Its publicly available materials primarily describe a research and clinical-development operation; specific commercial products, geographic markets, and broader leadership details should be confirmed through the company’s latest regulatory filings and corporate disclosures.View Estrella Immunopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?YETI Beat on Earnings, But Its Sales Tell a Different StoryCostco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsLightPath Technologies' Record Backlog Highlights a Bigger Defense Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
